1,4-Diaminocyclohexane, also known as trans-1,4-diaminocyclohexane, is a cyclic diamine with two amino groups in the 1 and 4 positions of the cyclohexane ring. It is a colorless solid with a melting point of 42-44 °C and a boiling point of 217 °C. 1,4-Diaminocyclohexane is a versatile building block in organic synthesis and finds applications in various fields.
The synthesis of 1,4-diaminocyclohexane typically involves the reduction of 1,4-cyclohexanedione or its derivatives. One common method involves catalytic hydrogenation of 1,4-cyclohexanedione using a metal catalyst such as Raney nickel.
1,4-Diaminocyclohexane has been investigated for its potential medicinal properties. Studies have shown that it exhibits anti-inflammatory and analgesic effects, suggesting potential therapeutic applications. Additionally, its ability to form complexes with metal ions has led to its exploration in the development of catalysts and materials.
The importance of 1,4-diaminocyclohexane arises from its unique structural characteristics and its ability to participate in a wide range of chemical reactions. Its rigid cyclic structure and the presence of two amino groups provide opportunities for diverse synthetic transformations and complex formation.
Research on 1,4-diaminocyclohexane aims to understand its fundamental properties, explore its potential applications, and develop novel synthetic methodologies for its production. Ongoing investigations are focused on optimizing its synthesis, developing new derivatives with improved properties, and elucidating its biological activity.'
1,4-diaminocyclohexane: RN given refers to compound with no isomeric designation
ID Source | ID |
---|---|
PubMed CID | 18374 |
SCHEMBL ID | 65155 |
SCHEMBL ID | 55128 |
SCHEMBL ID | 31990 |
SCHEMBL ID | 8230252 |
MeSH ID | M0235320 |
Synonym |
---|
EN300-20273 |
trans-1,4-cyclohexyldiamine |
1,4-cyclohexanediamine, trans- |
4-aminocyclohexylamine |
1,4-diaminocyclohexane |
trans-1,4-cyclohexanediamine |
1,4-cyclohexylenediamine |
cyclohexane-1,4-diamine |
hexahydro-1,4-phenylenediamine |
ccris 6490 |
einecs 221-483-6 |
brn 1919871 |
trans-cyclohexane-1,4-diamine |
trans-1,4-diaminocyclohexane, >=98.0% (gc) |
1,4-cyclohexanediamine |
3114-70-3 |
C1798 |
cis-1,4-diaminocyclohexane |
2615-25-0 |
cis-1,4-cyclohexanediamine |
C1426 |
trans-hexahydro-1,4-phenylenediamine |
15827-56-2 |
trans-1,4-diaminocyclohexane |
AKOS006345490 |
AKOS000120386 |
cis-cyclohexane-1,4-diamine |
A809914 |
1,4-cyclohexanediamine, cis- |
A818218 |
A820739 |
1,4-diaminecyclohexane |
AKOS006341993 |
(1r,4r)-cyclohexane-1,4-diamine |
BP-12407 |
FT-0634673 |
FT-0634396 |
niosh/gu8751000 |
GU87510000 |
1,4-cyclohexanediamine, cis,trans- |
cis/trans-1,4-dch |
cis/trans-1,4-diaminocyclohexane |
cis/trans-1,4-cyclohexanediamine |
AM20070543 |
AM100652 |
BP-21225 |
SCHEMBL65155 |
SCHEMBL55128 |
SCHEMBL31990 |
1,4-cyclohexanediamine # |
J-503974 |
trans-1.4-diaminocyclohexane |
trans-1,4-cyclohexane diamine |
1,4-diaminocylcohexane |
(trans)-cyclohexane-1,4-diamine |
trans 1,4-cyclohexanediamine |
1,4-trans-cyclohexane-diamine |
1,4-diamino-cyclohexane |
1,4-trans diaminocyclohexane |
1,4-trans-cyclohexane diamine |
(4-aminocyclohexyl)amine |
trans-1,4-diamino-cyclohexane |
trans 1,4-diaminocyclohexane |
mfcd08276323 |
SCHEMBL8230252 |
DS-1098 |
W-109861 |
F8880-6604 |
DTXSID30185071 |
mfcd00035862 |
mfcd00075174 |
J-009489 |
BS-15836 |
(1s,4s)-cyclohexane-1,4-diamine |
FS-4055 |
AMY37608 |
3,3,5,5-tetrachlorodiphenyldisulfide |
D83402 |
T70349 |
SY112211 |
A936200 |
cis-1,4-cyclohexanediamine dihydrochloride, >/=98% |
DTXSID70884854 |
DTXSID90883869 |
A877352 |
trans-1,4-diaminocyclohexane;trans-1,4-cyclohexyldiamine |
I11239 |
EN300-117144 |
CS-0096883 |
CS-0096882 |
EN300-96690 |
SY026431 |
Z104477550 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.93) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |